Divis Khaira

1.6k total citations
8 papers, 784 citations indexed

About

Divis Khaira is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Divis Khaira has authored 8 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Epidemiology and 2 papers in Molecular Biology. Recurrent topics in Divis Khaira's work include Cytomegalovirus and herpesvirus research (3 papers), Cell death mechanisms and regulation (2 papers) and Lung Cancer Research Studies (2 papers). Divis Khaira is often cited by papers focused on Cytomegalovirus and herpesvirus research (3 papers), Cell death mechanisms and regulation (2 papers) and Lung Cancer Research Studies (2 papers). Divis Khaira collaborates with scholars based in United States, South Africa and Canada. Divis Khaira's co-authors include Charles M. Rudin, Leena Gandhi, Andrew Krivoshik, Philip M. Hemken, Christine L. Hann, Sari H. Enschede, Todd Busman, Cathy E. Nolan, Geoffrey I. Shapiro and D. Gandara and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Hematology.

In The Last Decade

Divis Khaira

8 papers receiving 769 citations

Peers

Divis Khaira

ONCOL

MB

IMMUN

PRM

EPIDE

Elgilda Musi United States

Zi‐Jie Long China

Alok R. Singh United States

Antonia N. Policheni Australia

Jean‐René Pallandre France

Da-Gong Wang United Kingdom

Venturina Stagni Italy

Benoît Thibault France

Mark J. Sinnamon United States

Miriam Canavese United States

Elgilda Musi United States

Divis Khaira

304 ×0.8

ONCOL

450 ×1.2

MB

117 ×0.5

IMMUN

148 ×1.5

PRM

71 ×0.8

EPIDE

Citations per year, relative to Divis Khaira Divis Khaira (= 1×) peers Elgilda Musi

Countries citing papers authored by Divis Khaira

Since Specialization

Citations

This map shows the geographic impact of Divis Khaira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Divis Khaira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Divis Khaira more than expected).

Fields of papers citing papers by Divis Khaira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Divis Khaira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Divis Khaira. The network helps show where Divis Khaira may publish in the future.

Co-authorship network of co-authors of Divis Khaira

This figure shows the co-authorship network connecting the top 25 collaborators of Divis Khaira. A scholar is included among the top collaborators of Divis Khaira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Divis Khaira. Divis Khaira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Lee, King, et al.. (2011). Long-Term Stable Disease of Stage IV Pancreatic Neuroendocrine Tumors and Without Significant Adverse Effect by CPI-613, an Investigational Novel Anti-Cancer Agent. 1(3). 137–145. 9 indexed citations

2.

Gandhi, Leena, D. Ross Camidge, Moacyr Oliveira, et al.. (2011). Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology. 29(7). 909–916. 462 indexed citations

3.

Vonderheide, Robert H., Patricia LoRusso, Magi Khalil, et al.. (2010). Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. Clinical Cancer Research. 16(13). 3485–3494. 234 indexed citations

4.

Nemunaitis, John, Mitchell Rosenberg, Divis Khaira, et al.. (2009). A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Clinical Oncology. 27(15_suppl). 3535–3535. 12 indexed citations

5.

Roberts, Andrew W., Leena Gandhi, Owen A. O’Connor, et al.. (2008). Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263. Journal of Clinical Oncology. 26(15_suppl). 3542–3542. 11 indexed citations

6.

Torok‐Storb, Beverly, Bettina C. Fries, Daniel Stachel, & Divis Khaira. (1993). Cytomegalovirus: variations in tropism and disease.. PubMed. 7 Suppl 2. S83–5. 8 indexed citations

7.

Fries, Bettina C., Divis Khaira, M. S. Pepe, & Beverly Torok‐Storb. (1993). Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients.. PubMed. 21(10). 1387–92. 19 indexed citations

8.

Torok‐Storb, Beverly, Paul J. Simmons, Divis Khaira, Daniel Stachel, & David Myerson. (1992). Cytomegalovirus and marrow function. Annals of Hematology. 64(S1). A128–A131. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact